Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 3:13:1003697.
doi: 10.3389/fphar.2022.1003697. eCollection 2022.

Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review

Xu Liu  1 , Xia Tian  1 , Zhipeng Ma  1 , Jiali Chen  1 , Qingsong Huang  1 , Peiyang Gao  2 , Chuantao Zhang  1
Affiliations

Efficacy and safety of glycyrrhizic acid preparation treating comorbid liver injury in COVID-19: A systematic review

Xu Liu et al. Front Pharmacol. .

Abstract

Background: No specific drug for COVID-19 has been found, and many studies have found that different degrees of liver injury often occurred after infection with COVID-19. Glycyrrhizic acid preparation (GAP) has been frequently used clinically, often combined with conventional treatments such as antiviral therapy, to improve the prognosis of COVID-19 and patients' liver function. Aims: To critically review and analyze clinical evidence on the efficacy and safety of GAP in the treatment of COVID-19 alone and COVID-19 with comorbid liver injury. Methods: A systematic literature review was performed following a sensitive searching strategy that examines all articles published in "WHO COVID-19 Research Database," "Cochrane Library," "VIP," "CNKI," "Wanfang," and "CBM" from 2020 to July 2022. Articles were evaluated by peer reviewers and used Joanna Briggs Institute (JBI) critical appraisal tools to complete the assessment of the risk of bias. Results: Ten clinical studies were finally included, involving 598 patients with COVID-19, of whom 189 were confirmed to be with comorbid liver injury. The main GAPs used are diammonium glycyrrhizinate and magnesium isoglycyrrhizinate, which have shown efficacy in improving liver function, inhibiting inflammation, and enhancing immunity. We are still seeking more related research. Conclusion: Glycyrrhizic acid preparations (mainly diammonium glycyrrhizinate and magnesium isoglycyrrhizinate) have a considerable clinical effect on improving liver function in patients with COVID-19 alone or with comorbid liver injury. Further studies on the use of GAP in the treatment of COVID-19 with comorbid liver injury and its mechanism are still needed. Systematic Review Registration: [www.crd.york.ac.uk/prospero], identifier [CRD42021234647].

Keywords: COVID-19; SARS-CoV-2; efficacy; glycyrrhizic acid preparation; liver injury; safety; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flow graph of the literature search.
FIGURE 2
FIGURE 2
Schematic diagram of the results.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abraham J., Florentine S. (2021). Licorice (Glycyrrhiza glabra) extracts-suitable pharmacological interventions for COVID-19? A review. Plants (Basel) 10, 2600(12), 10.3390/plants10122600 - DOI - PMC - PubMed
    1. Andersson U., Tracey K. J. (2011). HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29, 139–162. 10.1146/annurev-immunol-030409-101323 - DOI - PMC - PubMed
    1. Bloom P. P., Meyerowitz E. A., Reinus Z., Daidone M., Gustafson J., Kim A. Y., et al. (2021). Liver biochemistries in hospitalized patients with COVID-19. Hepatology 73 (3), 890–900. 10.1002/hep.31326 - DOI - PubMed
    1. Cai Q., Huang D., Yu H., Zhu Z., Xia Z., Su Y., et al. (2020). COVID-19: Abnormal liver function tests. J. Hepatol. 73 (3), 566–574. 10.1016/j.jhep.2020.04.006 - DOI - PMC - PubMed
    1. Cao Y., Shi H., Sun Z., Wu J., Xia Y., Wang Y., et al. (2019). Protective effects of magnesium glycyrrhizinate on methotrexate-induced hepatotoxicity and intestinal toxicity may Be by reducing COX-2. Front. Pharmacol. 10, 119. 10.3389/fphar.2019.00119 - DOI - PMC - PubMed

Publication types